Trial of Sodium Phenylbutyrate-Taurursodiol for ...
Sodium phenylbutyrate-taurursodiol slowed ALS functional decline (-1.24 vs. -1.66 points/month on ALSFRS-R) over 24 weeks compared to placebo, with no significant differences in secondary outcomes. Adverse events were mainly gastrointestinal. Larger trials are needed for further efficacy and safety evaluation.
Related Clinical Trials
Reference News
Trial of Sodium Phenylbutyrate-Taurursodiol for ...
Sodium phenylbutyrate-taurursodiol slowed ALS functional decline (-1.24 vs. -1.66 points/month on ALSFRS-R) over 24 weeks compared to placebo, with no significant differences in secondary outcomes. Adverse events were mainly gastrointestinal. Larger trials are needed for further efficacy and safety evaluation.